Your CMS GUIDE Partner for Specialized Dementia Support

Learn more

Author

Peter Wallach

February 9, 2024
Neurodegenerative Care Means Cutting-Edge Treatments and Clinical Trials
By integrating emerging treatments and clinical studies into personalized care, Synapticure accelerates research and democratizes access to the latest therapies.

.avif)
February 9, 2024
Enhancing ALS Care with Clene's Expanded Access Program
Synapticure's virtual platform enhances accessibility to Clene's Expanded Access Program for people living with ALS

February 9, 2024
Continuing the Fight for Improved Care and Support
Synapticure’s co-founders bring the fight for improved care to the White House

February 9, 2024
It’s A Wonderful Life: Gratitude for Friendships on our Journey
A story of friendship, overcoming adversity, building a movement and changing healthcare

February 9, 2024
Synapticure’s Co-founders Featured on CBS Sunday Morning: “Fighting the good fight against ALS”
Lee Cowan shared the personal and professional journey of Synapticure’s co-founders who are “Fighting the good fight against ALS”

February 9, 2024
How The Dementia GUIDE Model Enhances Caregiving
Synapticure will participate in a first-of-its-kind CMS model to support patients and caregivers living with dementia

February 9, 2024
EAPs Explained: What are Expanded Access Programs and How to Participate
What are EAPs? Learn about Expanded Access Programs and how to participate in them with Synapticure

February 9, 2024
ALS: The Disease that Stopped “The Iron Horse,” Lou Gehrig
On June 2nd, MLB honors Lou Gehrig to raise awareness about ALS

February 9, 2024
How we support partner clinics
Synapticure empowers physician partners by supplementing their care in ways customized to the clinic

February 9, 2024
How Peter Wallach honors his brother (and co-founder)
My name is Peter Wallach and I am the Chief Financial Officer & Co-Founder at Synapticure. After my brother was diagnosed with ALS our family founded Synapticure to help him and others.